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NATURe CHeMICAL BIOLOgy modifications within its α 1-α 2 IDR, we first tested whether phosphorylation of S62 or deamidation of N52 and N66 influenced the affinity of Bcl-xL for its proapoptotic BH3 partners. We used isothermal titration calorimetry (ITC) to determine the binding affinities of synthetic peptides spanning the BH3 domains of the proapoptotic proteins BID and BIM for wild-type Bcl-xL, a Bcl-xL S62E phosphomimetic mutant that has reduced antiapoptotic function in cells 28, 29 , and Bcl-xL deamidated in vitro at N52 and N66 (ref. 31 ; Fig. 1c-e and Supplementary Table 1 ). These constructs were truncated at residue 209 and therefore lacked the C-terminal membrane insertion domain of Bcl-xL used in numerous past structural studies of Bcl-xL [32] [33] [34] . This C-terminal-truncated form of Bcl-xL was recently shown to structurally mimic the mitochondrial-membraneanchored form of Bcl-xL 35 . Wild-type Bcl-xL bound tightly to BID and BIM BH3 peptides with dissociation constants (K D ) of 13 and 17 nM, respectively, in agreement with previous reports 8, 36 . By contrast, both Bcl-xL S62E and deamidated Bcl-xL exhibited reduced affinities for BID and BIM BH3 peptides, with K D values ranging between 61 and 340 nM. These results suggested that these modifications in the α 1-α 2 IDR downregulate the antiapoptotic function of Bcl-xL by reducing its affinity for proapoptotic BH3 domains.
The IDR of Bcl-xL binds to α2-α3 of its folded core. The evidence that post-translational modifications altered binding of Bcl-xL to proapoptotic BH3 partners suggested that the α 1-α 2 IDR may influence the conformation of the folded, α -helical core of Bcl-xL, which displays the hydrophobic BH3 domain binding groove. Analysis using two-dimensional (2D) NMR spectroscopy revealed marked differences in the chemical-shift values of residues within α 2 and α 3 of Bcl-xL constructs containing and lacking the unmodified α 1-α 2 IDR (the latter termed Bcl-xL Δ IDR; Fig. 2a,b and Supplementary  Fig. 1a ). Examination of published structures of Bcl-xL and Bcl-xL Δ IDR 8, 9, 32, 37 showed that these chemical-shift differences correspond to subtle repositioning of the α 2-α 3 segment, with α 3 extending further from α 4-α 5 in the Δ IDR construct ( Supplementary Fig. 1b ). Similar chemical-shift differences in the 2D 1 H- 15 N-TROSY spectrum of wild-type Bcl-xL were observed with two α 1-α 2 IDR modified forms of Bcl-xL, including those with the S62E mutation or with deamidation of N52 and N66 (Fig. 2c,d and Supplementary  Figs. 1c,d-g) . These perturbations were particularly pronounced in the α 2-α 3 region of Bcl-xL, with more sparse perturbations in the neighboring α 4 and α 5 regions. These observations suggest that the IDR may cause subtle, but widespread, conformational changes within the hydrophobic BH3 domain binding groove comprised of these helices ( Supplementary Fig. 1b ).
Next, we sought to identify the regions of the α 1-α 2 IDR that interacted with α 2 and α 3 of the Bcl-xL folded core. Using ITC, we determined that synthetic peptides spanning residues 44-72 of the Bcl-xL IDR (IDR bound in trans to Bcl-xL Δ IDR and that phosphorylation of S62 or deamidation of N52 and N66 (for example, peptides with N52D and N66D) enhanced this interaction. For example, the K D value for the IDR 44-72 peptide with N52D and 
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N66D was 6 μ M, that with phosphorylated S62 was 36 μ M, and that with the wild-type peptide was 270 μ M ( Supplementary Fig. 2a-e ). Titration experiments using NMR confirmed that these modified peptides bound to the helical core of 15 N-labeled Bcl-xL Δ IDR, with the largest chemical-shift perturbations (CSPs) observed for residues in α 2, α 3 and α 8 ( Supplementary Fig. 3a -i). Furthermore, shorter α 1-α 2 IDR peptides (residues 52-66) with phosphorylated S62 (IDR 52-66 pS62) or the S62E mutation caused CSPs that were localized within the α 2-α 3 region of Bcl-xL Δ IDR ( Fig. 2e,f and Supplementary Fig. 3j-m) . Interestingly, the trajectories of perturbed resonances in peptide titration NMR experiments exhibited a nonlinear dependence on peptide concentration, suggesting a three-state behavior, possibly due to a peptide-binding-induced conformational change within the helical core of Bcl-xL Δ IDR ( Supplementary Fig. 4a ). At low concentrations of titrated IDR peptide, most perturbed resonances of Bcl-xL Δ IDR shifted toward the direction of the corresponding resonance in the spectrum of wild type, IDR-containing Bcl-xL. This observation suggests that, in the absence of IDR post-translational modifications, the α 1-α 2 IDR transiently interacts in cis with the folded core of Bcl-xL.
To gain further insight into the structural details of the IDRcore interaction and the ways that post-translational modifications modulate Bcl-xL antiapoptotic function, we monitored CSPs in 1 H-15 N TROSY spectra of 15 N-labeled Bcl-xL Δ IDR, initially complexed with an unlabeled BID BH3 domain peptide, upon titration of the IDR 44-72 pS62 peptide ( Supplementary Fig. 4b,d ). Many resonances exhibited large CSPs and shifted toward the same frequencies as seen upon titration of the same peptide into apo Bcl-xL Δ IDR ( Supplementary Fig. 4e ). Several resonances corresponding to residues within the BH3 binding groove exhibited large CSPs that were similar to the frequencies observed with apo Bcl-xL. This effect was especially pronounced for the resonance of R139, which is engaged in a conserved electrostatic interaction with an aspartic acid side chain in BH3 binding partners. Correspondingly, in a competition fluorescence anisotropy assay, a fluorescein-labeled BID BH3 (FAM-BID BH3) peptide was partially displaced from Bcl-xL Δ IDR by titration of the IDR 44-72 pS62 peptide ( Supplementary  Fig. 4f ,g). These NMR and fluorescence anisotropy titration results suggest that the interaction of the α 1-α 2 IDR with the folded core destabilizes complexes of Bcl-xL with proapoptotic BH3 partners, providing a mechanism for downregulation of its antiapoptotic activity. Although the affinities of these in trans IDR-folded-core interactions are considerably lower than the tight Bcl-xL-BH3domain interactions, covalent linkage of the IDR and folded core in full-length Bcl-xL enhances the in cis IDR-folded-core interaction, enabling allosteric inhibition of the high-affinity BH3-domain-BH3-domain binding groove interaction.
IDR phosphorylation enhances binding to the folded core. We next sought a mechanistic explanation that would correlate (i) the decreased affinity of Bcl-xL for proapoptotic BH3 partners due to the α 1-α 2 IDR S62E phosphomimetic mutation or N52 and N66 deamidation and (ii) the enhanced interaction of the α 1-α 2 IDR with the α 2-α 3 region of Bcl-xL due to functionally comparable modifications (S62 phosphorylation or N52D and N66D mutations). We analyzed published structures of apo Bcl-xL and its various BH3-bound forms, which revealed a marked repositioning of the C terminus of α 2 and the entire α 3 relative to α 4-α 5 and other parts of the BH3 binding groove upon BH3 binding. As noted previously 8, 38 , this BH3 binding-induced rearrangement involves opening the binding groove to accommodate the α -helical BH3 domain 7,32 ( Fig. 3a ). Based on these observations, we hypothesized that the interaction of the α 1-α 2 IDR with the α 2-α 3 region of Bcl-xL hinders groove opening and antagonizes binding to BH3 domains.
We tested this hypothesis by using NMR to determine the solution structure of a modified form of the α 1-α 2 IDR bound to the folded core of Bcl-xL. { 1 H}-15 N heteronuclear nuclear Overhauser effect (NOE) spectra for Bcl-xL with the S62E phosphomimetic mutation showed that residues within the α 1-α 2 IDR exhibited reduced flexibility in comparison to wild-type Bcl-xL ( Supplementary Fig. 5a-d ), which allowed characterization of α 1-α 2 IDR-folded-core interactions. The similarity of patterns and magnitudes of CSPs induced in NMR spectra of Bcl-xL Δ IDR by in trans titration of IDR 52-66 peptides containing the S62E mutation and phosphorylated S62 ( Supplementary Fig. 3l ,m) indicated that these two peptides bound in trans to Bcl-xL Δ IDR in comparable manners and with very similar affinities. This observation supported the idea that the in cis α 1-α 2 IDR-folded-core interaction 
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in Bcl-xL S62E reflected that associated with phosphorylation of S62. Three dimensional 1 H-15 N-or 1 H-13 C-edited NOE correlation spectroscopy (NOESY) spectra of Bcl-xL S62E exhibited many 1 H-1 H NOE cross-peaks between residues in the α 1-α 2 IDR and those in the folded protein core, enabling structure determination of Bcl-xL S62E in an 'α 1-α 2 IDR inhibited' conformation ( Fig. 3b,c and Supplementary Fig. 5e ,f). Some of these cross-peaks were also detected, with weaker intensities, in corresponding spectra of the wild-type protein ( Supplementary Fig. 5f ). In particular, the aromatic side chain protons of W57 exhibited numerous cross-peaks with shielded methyl resonances corresponding to aliphatic residues in the core of the protein, including L150 and L108.
In the structure of Bcl-xL S62E, the aromatic side chain of W57 and other aliphatic residues, including I51 and L59, were buried inside a small, hydrophobic groove between α 3 and the C termini of α 5 and α 1, buttressing one face of α 3 positioned opposite that engaged in the BH3 binding groove. The negatively charged side chains of D61 and, particularly, E62, were positioned beside a positively charged surface patch of the Bcl-xL core formed by the cluster of arginine residues including R100, R102, and R103 ( Fig. 3c and Supplementary Fig. 5g ). This cluster of arginine residues may thus provide an electrostatic docking site that stabilizes the various hydrophobic and polar α 1-α 2 IDR-folded-core interactions described above. The side chains of N52 and N66, which become negatively charged upon deamidation, were also proximal to the arginine-residue cluster in the structure of Bcl-xL S62E, suggesting a similar mechanism of stabilization for the α 1-α 2 IDR-folded-core interaction upon N66 deamidation ( Supplementary Fig. 5h ).
The α 1-α 2 IDR-folded-core interaction observed in the solution structure of Bcl-xL S62E exhibited a closed conformation of the BH3 binding groove that is incompatible with proapoptotic BH3 domain binding partners. In addition to this allosteric regulation of BH3 binding, the α 1-α 2 IDR-folded-core interaction also directly competes with the binding of p53 to Bcl-xL ( Supplementary Fig. 6a ), as shown using a fluorescence anisotropy assay ( Supplementary  Fig. 6b ,c). The three arginine residues within α 2-α 3 of Bcl-xL that bind the modified α 1-α 2 IDR are also present in Bcl-2 ( Fig. 3d ), which is also phosphorylated within the α 1-α 2 IDR 14-16 , suggesting a common mechanism of PTM-dependent autoregulation. Other Bcl-2 protein family members, including Mcl-1, Bax, and Bak, exhibit similar core structures but considerably shorter α 1-α 2 IDRs that lack the PTM sites 39, 40 (Fig. 1a ) and the cluster of surfaceexposed arginine residues (Fig. 3d ).
Similarity between solution and nanodisc-anchored Bcl-xL.
Bcl-xL is known to localize to the cytoplasm, as well as to mito- Supplementary Fig. 10 ). Red, acidic residues; blue, basic residues; and green, aromatic residues. e-g, ITC thermographs and curve fits for titrations of a BID BH3 domain peptide into Bcl-xL R103E (e), Bcl-xL S62E R103E (f), and deamidated Bcl-xL R103E (g). K D values are the average and s.e.m. of two independent titrations.
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NATURe CHeMICAL BIOLOgy chondrial and other cellular membranes (summarized in ref. 35 ); however, the in vitro structural results described above regarding interactions between the α 1-α 2 IDR and the Bcl-xL folded core were performed in the absence of membranes. To investigate the conformational features of Bcl-xL in the presence of membranes, we analyzed 15 N-labeled full-length Bcl-xL (including the 22-residuelong C-terminal transmembrane domain) anchored to membrane mimetic nanodiscs using NMR spectroscopy. The 2D 1 H-15 N HSQC spectrum of nanodisc-anchored, full-length Bcl-xL ( Supplementary  Fig. 8a , magenta spectrum) was similar to that of Bcl-xL (lacking the C-terminal transmembrane domain) recorded in aqueous solution, for which resonances are assigned ( Supplementary Fig. 8a , orange spectrum); however, due to the large aggregate size of nanodisc-anchored, full-length Bcl-xL and the lower protein concentration, the former spectrum exhibited broader resonances and reduced signal intensity. The similarity of these two spectra allowed the assignment of a large portion of the dispersed resonances for nanodisc-anchored, full-length Bcl-xL (103 of 226 possible nonproline HN resonances; Supplementary Fig. 8a,c,d) . The assigned resonances span both the folded core and α 1-α 2 IDR of nanodiscanchored Bcl-xL and exhibit small CSPs (< 0.12 p.p.m.) relative to the spectrum of Bcl-xL in solution. In particular, small CSPs were observed for several resonances within the α 1-α 2 IDR and the region of the folded core that binds the α 1-α 2 IDR (resonances labeled in red and blue, respectively, in Supplementary Fig. 8a) . Notably, the indole resonance of W57 within the α 1-α 2 IDR, which binds to the folded core (see above), exhibited chemical-shift values that were essentially identical in the two samples ( Supplementary Fig. 8a , inset). These results are consistent with previous results from Yao, et al. 35 , which showed through the analysis of 2D 1 H- 15 N HSQC spectra that, in the absence of residues 45-84 of the α 1-α 2 IDR, the folded core of nanodisc-anchored Bcl-xL closely resembled that of solution Bcl-xL lacking the C-terminal transmembrane domain. These results also showed that the C-terminal transmembrane domain was inserted into the lipid bilayer of nanodiscs. Our results show that the presence of the α 1-α 2 IDR does not alter the mechanism of nanodisc anchoring or the conformation of the folded core of Bcl-xL. Furthermore, our results demonstrate that interactions between the α 1-α 2 IDR and the folded core of Bcl-xL are preserved in nanodisc-anchored, full-length Bcl-xL. Though the nanodiscs used here do not mimic the lipid composition and dynamics of the outer mitochondrial membrane, our results do suggest that the autoregulatory interactions between the α 1-α 2 IDR and the folded core of Bcl-xL discussed above for solution Bcl-xL may be preserved in mitochondrial Bcl-xL. The cellular results discussed below further support this view (see below).
The α2-α3 Arg cluster senses IDR modifications. Based upon our structural investigations of Bcl-xL S62E, we hypothesized that electrostatic interactions between a positively charged cluster of arginine residues between α 2 and α 3 and negatively charged moieties introduced by post-translational modifications within the α 1-α 2 IDR mediate allosteric control of the BH3-domain binding and antiapoptotic activity of Bcl-xL. To test this hypothesis, we introduced a charge-reversal mutation of Arg103 to Glu (R103E) within the cluster of three arginines between α 2-α 3 in Bcl-xL (Fig. 3d ). This arginine residue, among the three in the cluster, is solvent exposed, and its side chain is oriented outside the BH3-domain binding groove, enabling this mutation to alter binding to the α 1-α 2 IDR without modifying the core domain structure. ITC measurements showed that Bcl-xL R103E containing the wild-type α 1-α 2 IDR tightly bound to BH3 peptides, although with somewhat lower affinities (higher K D values) than wild-type Bcl-xL ( Fig. 3e and Supplementary Table 1 ). However, the BH3 binding affinity of this mutant was insensitive to mutation of Ser62 to Glu (S62E) or deamidation of N52 and N66 (Fig. 3f,g) . These results support our proposal that PTMs promote interactions with α 3 of the Bcl-xL folded core by increasing the negative charge of the α 1-α 2 IDR, resulting in (i) direct inhibition of p53 binding and (ii) allosteric reduction of the affinity of the BH3 binding groove for proapoptotic BH3 domains.
To assess the biological relevance of this mechanism, we determined the antiapoptotic activity of wild-type Bcl-xL and autoregulation-defective mutants in HeLa cells through expression of cerulean fluorescent protein (CFP)-fused forms of Bcl-xL. Unlike the constructs used for in vitro studies, these encoded full-length Bcl-xL, including the C-terminal-membrane insertion domain. Because our in vitro results used Bcl-xL constructs lacking the C-terminal segment, we used full-length Bcl-xL, which normally can partition between cytosolic and mitochondrial membrane localization, to test our mechanistic hypotheses. Cells were transfected with vectors that encoded CFP, wild-type CFP-Bcl-xL, CFP-Bcl-xL S62E, CFP-Bcl-xL R103E, and CFP-Bcl-xL S62E, R103E (Fig. 4) . The CFP fusion was introduced to enable selection of cells with comparable expression levels using FACS. Transfected cells were subjected to several levels of ultraviolet (UV) irradiation and analyzed by FACS for CFP expression and Annexin V staining, an established early apoptosis marker 41 (Fig. 4a,c and Supplementary Fig. 7 ). These assays indicated that expression of wild-type Bcl-xL protected against UV-induced apoptosis and that protection was reduced by the S62E phosphomimetic mutation, as previously reported 28, 29 (Fig. 4b ). The R103E mutant was also less effective than wild-type Bcl-xL at protecting UV-irradiated cells against apoptosis. In the presence of the R103E mutation-predicted to disrupt the α 1-α 2 IDR-mediated autoinhibitory mechanism-introduction of the S62E mutation did not further reduce protection (Fig. 4c ). This observation agreed with in vitro ITC binding assays (Fig. 3e,f) and confirmed that a reduction in positive charge at the α 2-α 3 region of Bcl-xL prevented the stabilization of its inhibitory α 1-α 2 IDR-folded-core interaction driven by negative charges at position 62. Western blot analysis confirmed that all CFP-labeled Bcl-xL constructs were similarly expressed and did not experience differential degradation (Fig. 4d) , validating that the cellular consequences of the mutations were due to their effects on the affinity of Bcl-xL for its proapoptotic binding partners. Fluorescence cell imaging showed that the CFP-labeled Bcl-xL constructs exhibited comparable localization to intracellular membranes (those of mitochondria and ER), which was not altered upon UV irradiation ( Supplementary Fig. 9 ). This observation indicated that mutation of residues within the IDR, or those that interact with the IDR, did not alter the membrane localization of Bcl-xL. However, these mutations did alter Bcl-xL function, strongly suggesting that the α 1-α 2 IDR-dependent autoregulatory mechanism functions similarly in both C-terminally truncated Bcl-xL constructs in in vitro assays and in full-length Bcl-xL in cells, of which a substantial proportion is anchored to mitochondrial membranes ( Supplementary Fig. 9 ).
Expression of wild-type Bcl-xL or Bcl-xL R103E was associated with low level, UV-induced phosphorylation of S62 (Fig. 4d) . However, the observation that Bcl-xL S62E was a poorer inhibitor of apoptosis than the wild-type protein suggested that S62 phosphorylation was incomplete under these UV treatment conditions. Conversely, the S62E mutant, representing stoichiometric phosphorylation of this residue, enabled maximal, α 1-α 2 IDR-dependent downregulation of Bcl-xL's antiapoptotic activity.
Finally, we immunopurified the CFP-Bcl-xL constructs and analyzed the level of co-immunoprecipitation of the proapoptotic partners BIM, BAX (a proapoptotic effector that exhibits a BH3 domain that binds to and is inhibited by Bcl-xL 42 ) and p53. Both BIM and BAX exhibited substantial co-immunoprecipitation with most of the CFP-Bcl-xL constructs, but not with the S62E mutant (Fig. 4d ). This observation is in agreement with our ITC and FACS results showing a reduction in BH3 binding and antiapoptotic activity, respectively,
NATURe CHeMICAL BIOLOgy of Bcl-xL S62E compared to wild-type Bcl-xL and a lack of any further effect of the S62E mutant when introduced into the R103E mutant ( Fig. 4a-c) . These co-immunoprecipitation assays reported on the formation of complexes of Bcl-xL with endogenous, fulllength, BH3 domain-containing proteins in cells and agreed with our in vitro binding assays performed with synthetic BH3 domain peptides.
Intriguingly, although cells expressing Bcl-xL R103E exhibited higher levels of apoptosis than those expressing wild-type Bcl-xL, both constructs displayed similar abilities to sequester BIM and BAX (as monitored by co-immunoprecipitation; Fig. 4d ). However, the R103E Bcl-xL mutation was previously shown to disrupt binding to p53 in vitro 8 and was associated with reduced sequestration of p53 in UV-treated cells (Fig. 4d) , whereas in vitro it only modestly reduced Bcl-xL binding to proapoptotic BH3 domains (Figs. 1c and 3e and Supplementary Table 1 ). These observations suggest that the heightened apoptosis in cells expressing Bcl-xL R103E was due to its reduced ability to sequester p53. Overall, the results of our cellular assays support that the S62E phosphomimetic mutation reduced antiapoptotic activity by (i) directly reducing sequestration of p53 and (ii) allosterically reducing sequestration of proapoptotic Bcl-2 family proteins with BH3 domains. PTMs within the α 1-α 2 IDR promote interactions with the Bcl-xL folded core that directly inhibit p53 binding and simultaneously engage the allosteric pathway that modulates BH3-domain binding affinity.
Discussion
Synergy between IDRs and folded domains enhances the functional versatility of proteins 1 . Though folded domains are well adapted to perform catalysis and specific molecular recognition, IDRs, by virtue of their enrichment in modifiable amino acids and plasticity, and often through weak and transient interactions, can integrate diverse cellular signals to regulate the function of covalently bonded folded domains. The internal α 1-α 2 IDR of Bcl-xL has been known to integrate a variety of post-translational modification signals that modulate its antiapoptotic activity, but the mechanism of this autoregulation was thus far unknown. We have shown that the unmodified, > 50-residue-long α 1-α 2 IDR of Bcl-xL is highly flexible and solvent exposed, making it accessible to signaling inputs by enzymes that perform post-translational modifications. Upon phosphorylation on S62 or deamidation of N52 and N66, which both increase negative charge, the central region of the α 1-α 2 IDR binds to a cluster of arginine residues on the surface of the Bcl-xL folded domain, triggering a structural rearrangement within the distal binding groove that reduces the affinity for proapoptotic BH3 domains. NMR data suggested that autoregulatory interactions between the α 1-α 2 IDR and the folded core are similar for Bcl-xL in solution and nanodiscanchored Bcl-xL ( Supplementary Fig. 8 ). Together with data showing that the autoregulatory mechanism is active for Bcl-xL in cells, a substantial portion of which is localized to mitochondrial membranes, the NMR data suggest that this mechanism may be active for mitochondrial Bcl-xL. The evolution of internal IDRs within Bcl-xL and Bcl-2 affords responsiveness to diverse apoptotic signals that contribute to their specific functions. By experiencing post-translational modifications from different modifying enzymes, activated under various stress stimuli, these IDRs may differentially tune the activity of various antiapoptotic members of the Bcl-2 family of proteins under specific sets of circumstances, such as aberrant mitotic spindle assembly in the case of Bcl-xL 26 . This evolutionary strategy of specific autoregulation affords functional versatility within certain Bcl-2 family of proteins, all of which exhibit significant conservation of sequence and structure within their folded domains. For example, antiapoptotic Mcl-1 also contains a N-terminal autoregulatory IDR 43, 44 . In contrast, other antiapoptotic (Bcl-W and A1) and proapoptotic effector (BAX, BAK, and BOK) Bcl-2 family members lack autoregulatory IDRs (Fig. 1a ; Bcl-W, A1, and BOK not shown) 5 . The presence Supplementary Fig. 10 ).
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of IDRs within these apoptotic regulators may thus contribute to their role as 'molecular computers' capable of integrating a diverse range of pro-death and pro-survival signals to control cell fate. This integration occurs not only through modulation of the relative expression levels of various anti-and proapoptotic Bcl-2 family members, but also through the fine tuning of their affinities for various binding partners via post-translational modifications within autoregulatory IDRs, as illustrated here for Bcl-xL. The surface of Bcl-xL engaged by the post-translationally modified α 1-α 2 IDR is also a binding site for the DNA binding domain (DBD) of p53 (ref. 8 ); this latter interaction sequesters cytosolic p53 and inhibits BAX-dependent apoptosis 9 . The BH3 binding groove, comprised of α 4-α 5, and the abutted α 2-α 3 allosteric regulatory site serve as a two-way conduit for signal transmission (Fig. 5a-c) . In one direction, in response to DNA-damage-induced nuclear p53 activation 45 , PUMA binds to Bcl-xL, causing α 3 to unfold and allosterically triggering p53 release and apoptosis 9, 46 . In the opposite direction, post-translational modification of residues within the α 1-α 2 IDR in response to various apoptotic signals allosterically contracts the BH3 binding groove, freeing proapoptotic Bcl-2 family proteins to trigger apoptosis. In addition, by engaging the arginine cluster between α 2 and α 3, which otherwise binds to the DBD of p53, the IDR of Bcl-xL may release cytosolic p53 to activate BAX and apoptosis. This second proapoptotic mechanism further illustrates how functional versatility can be achieved by autoregulatory IDRs. Our study illustrates functional synergy between a folded domain and a disordered region of an apoptotic regulatory protein, Bcl-xL, and clearly demonstrates the capacity of IDRs within multidomain proteins to serve as conduits for the transmission of diverse signaling inputs.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41589-018-0011-x. The binding of PUMA to Bcl-xL directly displaces BH3-domain-containing proteins (for example, BIM) and allosterically releases p53 from the distal site, enabling the released proteins to induce apoptosis. This is termed the PUMA-bound, "α 3 unfolded" state. c, In a reversal of the allosteric pathway illustrated in b, PTMs within the α 1-α 2 IDR promote its interactions with the α 2-α 3 region of the folded core, displacing p53, and also allosterically remodeling the BH3 binding groove, releasing BH3 domain-containing proteins from Bcl-xL. As in b, the released proteins induce apoptosis. This is termed the IDR-bound, "α 3 inaccessible" state. 
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Total lysates were analyzed for GFP (mixed 7.1 and 13.1 clones; Roche; at 1:2,000 dilution), Bcl-xL (antibody clone H-5; Santa Cruz Biotechnology; at 1:200 dilution), S62-phosphorylated Bcl-xL (antibody sc-101644; Santa Cruz Biotechnology; at 1:200 dilution), BIM (antibody B7929, Sigma-Aldrich at 1:2,000 dilution), BAX (antibody clone N20; Santa Cruz Biotechnology; at 1:200 dilution), p53 (Antibody clone DO-1, Santa Cruz Biotechnology; at 1:1,00 dilution) and Actin (antibody clone 5C5; Santa Cruz Biotechnology; at 1:1,000 dilution). Immunoprecipitated samples were analyzed for GFP, BIM, BAX and p53 as described above. Validation of antibodies used in these assays can be found on the manufacturers' websites.
